Clinical and genetic aspects of menopausal hormone therapy - a modern paradigm. What changed COVID-19 pandemic?

In the modern paradigm of public health protection, much attention is paid to women in peri- and postmenopause, a personalized approach prevails. It generally recognized that pathogenetic therapy menopausal disorders hormone therapy. But COVID-19 pandemic has made its own adjustments routine strategy choosing (MHT). The purpose this review was analyze studies on dependence effectiveness MHT clinical genetic aspects context ongoing pandemic. highlights main risks for thromboembolic diseases coagulation complications characteristic COVID-19, discusses predispositions aggravate course post-COVID period, as well estrogens protecting vascular endothelium increasing number CD4+ T cells, providing an adequate immune response when infected with SARS-CoV-2. Numerous show severe are multifactorial nature cannot be unambiguously explained only by predisposition. However, development medicine, special should study can equally contribute occurrence healthy post-pregnancy period. data presented allow us conclude at population level, bring significant benefits during menopause due beneficial effect walls. Additional relationship between postcovid period users polymorphisms candidate genes determine thrombotic metabolic consequences required.